Drugs /

ublituximab

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.

Clinical Trials

View Clinical Trials for ublituximab

Ublituximab has been investigated in 15 clinical trials, of which 15 are open and 0 are closed. Of the trials investigating ublituximab, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), 7 are phase 2 (7 open), and 2 are phase 2/phase 3 (2 open).

MS4A1 Expression, CCND1 Overexpression, and IGH-CCND1 Fusion are the most frequent biomarker inclusion criteria for ublituximab clinical trials.

Chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma are the most common diseases being investigated in ublituximab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ublituximab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ublituximab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
tg-20, tgtx-1101, tg-1101, lfb-r603
Drug Categories [2]:
Immunotherapies, Therapeutic antibodies
Drug Target(s) [2]:
MS4A1
NCIT ID [1]:
C91078

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.